Biopharmaceutical firms deserve good public policy
True drivers of economic growth and job creation are industries that innovate. In Maryland, there is no better example of this dynamic at work than the biopharmaceutical industry, which is built on a foundation of innovation. From small biopharmaceutical start-ups, to larger companies, to the leading academic centers, to the National Institutes of Health, Maryland is bursting with exploration and achievement.
In 2010, there were more than 2,600 active clinical trials in Maryland across a range of conditions. Maryland biopharmaceutical companies invest billions in research and development to discover the new therapies that will someday have the potential to improve quality of life, treat once untreatable diseases and reduce health care costs.
And this kind of investment pays off. In March, Human Genome Sciences announced that its new breakthrough lupus drug won approval from the FDA the first drug approved for the condition in more than 50 years.
From the likes of Human Genome Sciences and MedImmune, which blazed the trail, to the many companies now eager to follow in their footsteps, such as Gliknik, Sequella, and Novavax, Maryland has a rich tradition of innovation and accomplishment. This tradition must be supported with sound investments and thoughtful public policy.
Kathleen T. Snyder
The letter writer is president and CEO of the Maryland Chamber of Commerce.